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Background.– Aim of this study was to shed a light on the current use of intrathe-
cal baclofen delivered by pump infusion in France for cerebral palsy in children
in order to standardize practice in that specific indication.
Methods.– We performed an observational study based on a standardized ques-
tionnaire sent to 29 pediatric PM&R services over the country. The questionnaire
consisted in closed responses (yes or no).
Results.– Twenty-four services responded to the questionnaire. Pre-test evalua-
tion was performed in 22 cases and post-test evaluation in 21 cases, and early
after implantation in 20 cases and late after implantation in 17 cases. Single
shot infusion was the test favored by PM&R physicians in 15 cases. The pump
was implanted in the subcutaneous tissue in 19 cases. Early complications were
observed in 16 cases after pump implantation. Late complications were observed
in 2 cases and consisted in catheter migration.
Conclusion.– In conclusion, the current study demonstrated large practice diver-
sity over the country and highlighted to potential for complications due to the
treatment. The follow-up of the treated patients was also non-uniform. It should
be of interest to develop nationwide standardized strategies in order to improve
and make uniform patient management.
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Background.– Intrathecal baclofen (ITB) therapy is a well-established treatment
of generalised and severe spasticity. Thirty years after the first implantation of
an ITB pump, it is time to make a balance of current possibilities as well as look
into challenges for the future.
Methods.– The scientific literature has been searched for ITB therapy in adults.
Furthermore, the algorithm of the “European working group for spasticity in
adults” and the activities of the “Ability network on the treatment of spasticity
in spinal cord injury” will be explored.
Results.– Whereas in the eighties most papers study safety and effectiveness
of ITB, more recent articles deal with complications, catheter position, cost-
effectiveness, functional outcome and timing of ITB or new indications.
Discussion/Conclusion.– Although the effectiveness of ITB has been proven,
many issues remain unclear. Therefore, further international collaboration on
assessment and outcome is necessary in order to develop an evidence-based
and widely applicable clinical pathway for indication, procedure and outcome
measurement of ITB therapy.
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Background.– Intrathecal baclofen therapy for children with severe spasticity
(Gross Motor Function Classification System IV-) is a successful therapy. How-
ever, in children with GMFCS I-III and dystonia patients, this therapy is not so
evident.
Method.– I’d like to elucidate our screening and follow-up methods based on
the experience of a multidisciplinary team approach at the University Hospital
Pellenberg on a large group of CP children.
Results.– It is important to assess the patients whole clinical presentation of
spasticity and spasticity-related problems, to make short-term and long-term
treatment goals. Re-assessment of treatment goals is necessary.
Conclusion.– Intrathecal baclofen therapy is not a solo therapy. How we can
evaluate this therapy then?
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